Albers Jeffrey W.
SEC Form 4 insider trading activity
Albers Jeffrey W. has filed 3 SEC Form 4 filings (9 transaction rows) across 2 companies, including SYRE, KYMR, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Aug 11, 2026.
On the most recent filing, Albers Jeffrey W. is listed as Director at Spyre Therapeutics, Inc. Inside the rolling window, Albers Jeffrey W. reported no open-market purchases and 2 open-market sales totaling $2.9M in SYRE and KYMR. The largest disclosed transaction in the window is a sale of 23,000 SYRE shares on Aug 7, 2026, worth $2.4M.
Companies traded
Other insiders at SYRE
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.9M
reported sales (SEC code S)
Companies
2
in the rolling window
Earlier trades
Open-market purchases and sales filed before the rolling 365-day window, kept from the original Form 4 filings.
| Date | Ticker | Type | Value |
|---|---|---|---|
| Oct 13, 2025 | KYMR | Sale | $296K |
Frequently asked questions
How many SEC Form 4 filings has Albers Jeffrey W. made?
Albers Jeffrey W. has filed 3 SEC Form 4 filings (9 transaction rows) across 2 companies, including SYRE, KYMR since 2025.
Which companies does Albers Jeffrey W. trade?
Albers Jeffrey W. has filed SEC Form 4 disclosures for 2 companies, including SYRE, KYMR.
When was Albers Jeffrey W.'s most recent SEC Form 4 filing?
Albers Jeffrey W.'s most recent SEC Form 4 filing on Tracefour is dated Aug 11, 2026.
What is Albers Jeffrey W.'s total buy and sell value in the current window?
Inside the rolling retention window, Albers Jeffrey W. bought $0 and sold $2.9M based on SEC Form 4 filings.
What was Albers Jeffrey W.'s largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 23,000 SYRE shares on 2026-08-07, worth $2.4M, per SEC Form 4 filings.